Showing results (181-190 of 1,232) with videos related to

Sort By:
Pageof 124
Current Medicinal Chemistry. Cardiovascular and Hematological Agents|August 24, 2004
AT1 receptor antagonistsI Verheijen, P M L Vanderheyden, J P De Backer, et al.
Thrombosis and Haemostasis|October 31, 1984
Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasmaE J Brommer, J H Verheijen, G T Chang, et al.
Carcinogenesis|July 1, 1989
Enhanced plasminogen activator production of Syrian hamster embryo cells transformed by chemicals or the c-Ha-ras oncogene: type of plasminogen activators involved and their contribution to the transformed phenotypeA J de Kok, H Sips, G T Chang, et al.
Advances in Experimental Medicine and Biology|June 13, 2008
Ovarian carcinogenesis: an alternative hypothesisJurgen M J Piek, Paul J van Diest, René H M Verheijen
The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS|May 9, 2014
Robotic transanal total mesorectal excision for rectal cancer: experience with a first caseP M Verheijen, E C J Consten, I A M J Broeders
Scientific Data|November 14, 2022
Multi-omics HeCaToS dataset of repeated dose toxicity for cardiotoxic & hepatotoxic compoundsMarcha Verheijen, Ugis Sarkans, Witold Wolski, et al.
Angewandte Chemie (International Ed. in English)|January 29, 2000
Fluorescence Detection from Single Dendrimers with Multiple ChromophoresGensch, Hofkens, Heirmann, et al.
Biochimica Et Biophysica Acta|October 17, 1983
Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activatorW Nieuwenhuizen, A Vermond, M Voskuilen, et al.
Biotechnology and Bioengineering|August 9, 2001
A priori analysis of metabolic flux identifiability from (13)C-labeling dataW A van Winden, J J Heijnen, P J Verheijen, et al.
Bioorganic & Medicinal Chemistry Letters|November 10, 2009
Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3KJeroen C Verheijen, Ker Yu, Lourdes Toral-Barza, et al.
Pageof 124